Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

RA Capital Management is a Boston-based investment firm focused on life sciences and healthcare. It provides venture and growth capital to public and private companies developing drugs, medical devices, diagnostics, and biotech tools, investing across stages from seed to IPO and follow-on financings. The firm often co-invests and takes board seats, pursuing opportunities in genetics, personalized medicine, cost-effective diagnostics, and nurse-enabled technologies. Its team combines expertise in biology, chemistry, and medicine with industry and business development experience. Founded in the early 2000s, RA Capital Management operates as an investment firm serving life sciences companies in the United States and Europe.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that focuses on biotechnology and life sciences companies in the United States. The firm seeks to invest in pharmaceutical and biotechnology ventures, including oncology and other healthcare technologies, with a goal of supporting entrepreneurs in turning ideas into developed therapies. It emphasizes collaboration with ambitious partners and aims to advance biotech innovation and important new therapies by providing capital and advisory support. The organization also operates as a registered investment adviser, offering investment advisory services to guide portfolio companies through growth and development.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Morningside is a venture capital firm that funds companies with novel science and technology. It pursues a long-term, value-building approach and emphasizes ethical conduct. Based in the greater Boston area, the firm has experienced professionals with backgrounds across life sciences, digital health, artificial intelligence, materials and technology. Established in 1986 as a family office for the Chan family, Morningside has supported education, research and healthcare through charitable commitments to institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Vivo Capital is a global healthcare investment firm based in Palo Alto with offices in Asia. Founded in 1996, it focuses on investing in and building high-quality companies in the United States and China. The firm engages across multiple strategies, including growth equity, private equity (buyouts), venture capital, and public equity, and invests in biopharmaceuticals, medical devices, and healthcare services. With about 25 years of operation, it manages approximately 5.8 billion in assets and has participated in over 290 public and private companies worldwide. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, reflecting a hands-on approach to helping portfolio companies scale in major healthcare markets.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages of company development, with emphasis on discovery and development of novel therapeutics. It leverages deep investment, operating, and scientific expertise to take a hands-on approach to building companies. Since its inception, more than 65 portfolio companies have achieved successful acquisitions or IPOs, reflecting its track record of helping startups advance therapies, devices, and life sciences ventures. The firm focuses on medical devices, biotechnology, pharmaceuticals, and life sciences, including oncology. It aims to support early-stage and growth-stage companies across the United States, Canada, and Europe, enabling development across the healthcare continuum.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

Founded in 1849, Pfizer is a global pharmaceutical company dedicated to discovering and developing safe, effective, and affordable medicines. With a broad portfolio across various therapeutic areas, Pfizer focuses on wellness, prevention, treatment, and cures for diseases, including investments in emerging technologies to shape the future of healthcare.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. Based in Pasadena, California, it provides long-term strategic capital to innovative life sciences and technology companies developing breakthrough therapies, diagnostics, and platforms across biopharma, digital health, agrifoodtech, agtech, and related healthcare fields. Established in 1996, the firm invests across seed, early, and growth stages and leverages its deep industry knowledge, extensive investor networks, and scientific advisory resources to support portfolio companies. The unit also pursues opportunities at the intersection of real estate, life sciences, and technology, reflecting its parent company's sector focus and integrated ecosystem approach. It aims to help entities advance human health by partnering with founders to scale transformative technologies.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with additional offices in La Jolla, California; Montreal, Quebec; and Tokyo, Japan. It backs early to later-stage startups in life sciences and information technology across the United States and Europe, focusing on West Coast U.S. and developed European markets. In life sciences, the firm pursues clinical-stage pharmaceutical, biotechnology and medical technology companies, including drug discovery platforms and entities addressing diseases with unmet medical needs, covering therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it funds product-oriented software, enterprise software, service-provider software, and telecommunications infrastructure. Seed investments in both domains typically range from 0.1 million to 1 million, with initial rounds for technology commonly 3-5 million and life science rounds 5-15 million; total commitments generally span 5-15 million for tech and 15-30 million for life sciences. The firm seeks board seats when leading or co-leading early-stage investments.

Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.

Deep Track Capital is a venture capital firm focused on life sciences and biotechnology. Based in Greenwich, Connecticut, it partners with management teams of innovative public and pre-IPO companies, offering capital and strategic support through its network and expertise. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other investors, applying time and resources to help portfolio companies grow.

EcoR1 Capital is a San Francisco-based investment firm focused on biotechnology. It provides advisory and investment services to biotechnology companies, pursuing venture-style opportunities in both private and public markets and supporting therapies with potential patient impact. Founded in 2012, the firm emphasizes scientific innovation and translational research and draws inspiration from the EcoR1 restriction enzyme. As an investment adviser, EcoR1 Capital collaborates with clients and partners in the biotech sector to identify promising treatments and help companies address unmet medical needs.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, specializing in life sciences and biotechnology. It supports the translation of high-impact scientific discoveries into medicines for patients through a seed-led venture creation strategy that identifies and builds scalable companies with strong scientific foundations. The firm combines experienced scientists and career venture capitalists to select compelling opportunities and realize value, emphasizing early-stage investments in life sciences and technology. Atlas Venture also maintains a multi-disciplinary team able to advance startups from concept to clinical development and commercial viability.

Founded in 2001 and based in Zug, Switzerland, HBM Healthcare Investments is a venture capital firm focusing on the healthcare sector. It invests globally in mature emerging companies primarily in biotechnology/human medicine, diagnostics, and medical technology sectors.

Omega Funds is a Boston-based venture capital and private equity firm founded in 2004 that concentrates on early-stage investments in healthcare and biotech across North America and Western Europe, backing companies in life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Hercules Capital is a specialty finance company that provides senior secured loans and growth capital to privately held venture capital-backed companies across various stages of development in technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience, Hercules offers innovative financing solutions tailored to each company's capital structure and business objectives.

Kurma Partners is a Paris-based investment firm founded in 2009 that concentrates on financing innovation in healthcare and biotechnology across Europe. It targets early-stage and development capital for companies in life sciences, biotechnology, digital health, and related fields, and emphasizes collaborations with research institutes and hospitals to advance therapies and medical technologies from concept to clinical development. The firm operates as a specialist investor in Europe, supporting ventures that bridge scientific discovery and patient impact through equity investments and strategic guidance.

SR One is the corporate venture capital arm of GlaxoSmithKline, investing globally in early-stage life science companies pursuing innovative science with the potential to significantly improve medical care. Since 1985, SR One has invested about $800 million in more than 180 companies.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in San Diego, California. As a subsidiary of Tavistock Life Sciences, it specializes in investing in both private and public companies within the biotechnology and life science sectors. Boxer Capital focuses on a wide range of companies involved in the drug development lifecycle, from early stage preclinical discovery assets to late stage clinical and commercial entities. The firm aims to support the growth and advancement of biotechnology innovations through its strategic investments.

SOSV is a global venture capital firm that supports early-stage startups through active, founder-first development programs. Its flagship initiatives HAX and IndieBio provide facilities, engineering resources, services, and laboratory equipment to accelerate product development and prepare companies for subsequent funding rounds. SOSV focuses on deep technology across health, environmental, and cross-border software sectors, aiming to solve human and planetary health challenges. In addition to providing capital, the firm emphasizes intensive programmatic support to help portfolio companies move quickly from seed toward growth, including customer acquisition and scale. The firm operates globally with a bias toward startups targeting rapid international expansion, especially in Asia, and tends to back a small cohort of high-potential companies to accelerate their progress and attract leading investors.

Founded in 1996, MPM Capital is a global investment firm focused on the healthcare and life sciences sectors. It specializes in early-stage investments, typically ranging from $5 million to $50 million, with a primary focus on biotechnology, oncology, medical technology, and specialty pharma. The firm invests globally, with a concentration in North America, Europe, and Asia-Pacific.

Casdin Capital is a New York‑based investment firm founded in 2012 by Eli Casdin. The firm specializes in fundamental research and long‑short equity strategies focused on the life sciences and healthcare sectors, including oncology, digital health, and agtech. In addition to its public‑market fund, Casdin Capital invests in early‑stage to late‑stage private companies within these industries. It operates as a Registered Investment Adviser and, as of October 2020, managed approximately $2.2 billion in assets.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Canaan Partners is a San Francisco-based venture capital firm founded in 1987 that operates globally with offices in Israel and India. It focuses on early-stage investments in technology and healthcare, including software, fintech, enterprise/cloud, marketplaces, digital health, biopharma, and medtech, and it has a history of backing startups that achieve exits.

Founded in 2020, TCG Crossover is a venture capital firm dedicated to advancing disruptive medicines and supporting companies focused on improving patient lives. Based in Palo Alto with an additional office in New York City, the firm invests in both private and public biotechnology companies led by exceptional entrepreneurs.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, affiliated with Fidelity Investments. It backs technology and life sciences entrepreneurs across the Americas, Europe, and Asia, drawing on Fidelity’s experience in funding early-stage companies. The firm focuses on sectors such as healthcare IT, medtech, therapeutics, fintech, frontier technologies, crypto, and broader information technology and technology-enabled services. With a global network of regional teams and affiliated funds, F-Prime provides domain expertise, strategic guidance, and industry connections to help founders build durable companies. It operates with a long-term, founder-centric approach, emphasizing value creation rather than external fundraising pressures.

Founded in 2000, Aisling Capital is a New York-based investment firm focusing on mid-market and growth-oriented investments in life sciences, healthcare, and technology companies across the United States and Western Europe. The company aims to support leading global healthcare companies commercializing new products driven by biotechnology advancements.

Longitude Capital is a California-based investment firm focused on venture growth in life sciences, including biotechnology and medical technology companies. Founded in 2006, it targets both privately held and publicly traded life science companies and pursues a balanced portfolio of clinical-stage and commercial-stage assets with the potential for value creation within three to five years. The firm identifies opportunities through its broad industry network and thematic research into emerging therapeutic areas or sub-sectors, and uses a range of investment structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. It maintains offices in Menlo Park, Greenwich, and Boston and operates as a registered investment adviser.

Merck & Co. is a global biopharmaceutical company based in New Jersey that discovers, develops, and markets medicines and vaccines to treat cancer, infectious diseases, autoimmune disorders, and other conditions. The company maintains a strong cancer portfolio anchored by an immuno-oncology therapy platform led by Keytruda and a growing vaccine business including Gardasil for human papillomavirus. Its research arm, Merck Research Laboratories, focuses on discovering and developing therapies for cancer and neurodegenerative diseases. Merck also markets animal health products. Through its science-driven approach, Merck aims to deliver innovative products and therapies that improve patient outcomes worldwide.

VenBio is a California-based venture capital firm focused on life sciences, investing in early- to late-stage US companies with an emphasis on drug discovery. Based in San Francisco, the firm leads many investments and actively builds syndicates and management teams to support portfolio companies. VenBio aims to position its companies for potential acquisition by considering needs such as intellectual property, chemistry, manufacturing controls, and the clinical development pathway, including indication, trial design, endpoints, powering, and regulatory strategy. The team leverages its expertise to help portfolio companies advance scientifically and strategically, forging lasting relationships with leaders in the field. By combining depth in science with hands-on operational support, VenBio seeks to accelerate development and deliver meaningful medical innovations.

Frazier Management, L.L.C. is a private equity and venture capital firm established in 1991 and headquartered in Seattle, Washington, with additional offices in North America. The firm specializes in growth equity financing and engages in a variety of investment strategies, including incubation, expansion stage equity, and corporate divestitures. Frazier Management focuses primarily on the healthcare sector, actively investing in drug development, pharmaceutical services, medical devices, and healthcare information technology, among other areas. The firm seeks to support companies at various stages of development, from startups to established businesses, typically investing between $3 million and $100 million per transaction. Frazier prefers to take majority stakes and often acts as a lead investor, taking board seats in its portfolio companies. Its investment strategy emphasizes profitable companies with a strong EBITDA, particularly in the United States, Canada, and Europe, concentrating on key regions such as the Bay Area, San Diego, Seattle, Boston, and North Carolina.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab, with an office in Boston. It concentrates on seed- and early-stage investments in life sciences, healthcare and technology-related companies, including digital health and health technology. Its portfolio comprises firms in biopharmaceuticals, biotechnology, medical technology and related research instruments.

Founded in 1994, the European Investment Fund operates as a venture capital and private equity firm specializing in incubation, direct, secondary indirect, and fund of funds investments. It focuses on disruptive early-stage technology enterprises and supports micro, small, and medium-sized enterprises across Europe, primarily at early stages. The fund invests between €0.25 million and €60 million per transaction, with a preference for investing €130 million into private equity and venture capital funds.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.

SV Health Investors is a venture capital and growth equity firm focused on healthcare and life sciences. Headquartered in the United States with offices in Boston, San Francisco and London, the firm supports entrepreneurs who develop breakthrough medicines, devices and related technologies. It manages multiple private healthcare funds and has a 20-year track record in the US and Europe, investing across North America and Western Europe to advance innovative treatments and diagnostics. SV Health Investors aims to transform healthcare by backing early-stage and growth opportunities in biotechnology, medical devices and related sectors.

Third Rock Ventures is a Boston-based venture capital firm that specializes in start-up and early-stage investments in life sciences companies, including biotechnology, pharmaceuticals, medical devices, diagnostics, therapeutics, and related information technology and data applications. Founded in 2007, the firm focuses on transformational ventures in the United States and commonly makes substantial initial investments, often leading rounds and pursuing strategic collaborations with larger pharmaceutical and biotechnology companies. It emphasizes active involvement in its portfolio, sometimes taking key management roles to accelerate development, and seeks to support companies through strategic partnerships, milestones, and scale-up efforts. While headquartered in Boston, it maintains a presence in San Francisco to engage with the broader life sciences ecosystem.

Takeda Ventures is a strategic investment arm of Takeda Pharmaceutical Company Limited, focusing on direct and fund-of-fund investments in healthcare and life sciences sectors. It specializes in seed to mid-stage investments, with a primary focus on therapeutics, regenerative medicines, RNA/DNA modulation, and innovative protein/peptide biologics. The firm invests globally but has a strong presence in the United States, Canada, and Europe.

Mission BioCapital is a life science venture capital firm investing in early-stage companies within the biotechnology sector. Founded in Cambridge, Massachusetts in 2009, the company is known for its experienced leadership team and deep support provided to portfolio companies.